Author

Hai-Yan Li

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

A microdose cocktail and population pharmacokinetic study suggests potentially reduced CYP3A and P-gp activities in type 2 diabetes

Background Diabetes patients often exhibit suboptimal efficacy and adverse reactions, accompanied by pharmacokinetic (PK) changes, indicating drug-metabolizing enzymes and transporters (DMET) activities may change. This study aimed to determine whether type 2 diabetes affects DMET activities and quantify impact magnitu...

Ya-Fen Li, Jin Yang, En-Da Zhou et al. · Frontiers in Pharmacology · 0 citations

Clinical trial Open access Sep 2026

Pharmacokinetic and Pharmacodynamic Drug‐Drug Interactions Between Cofrogliptin and Metformin in Healthy Subjects: A Single‐Center, Single‐Arm, Phase I Study in China

Abstract This single‐center, single‐arm, Phase I study evaluated drug–drug interactions (DDIs) between cofrogliptin and metformin in healthy Chinese subjects. Twenty‐two subjects sequentially received metformin monotherapy (Days 1–4), cofrogliptin monotherapy (Days 6–34), and combination therapy (Days 38–47). Serial bl...

Cheng Cui, Na Liu, Chang Chu et al. · Clinical pharmacology in dru... · 0 citations

Open access Sep 2026

Pyridoxic Acid as a Novel Endogenous Biomarker for OAT-Mediated Clearance of Meropenem: A Population Pharmacokinetic Modeling and PK/PD-Response Analysis in Patients with Sepsis

PDA is a valuable translational biomarker for OAT-mediated clearance and is suggested to complement CLcr in characterizing meropenem clearance variability, establishing a key PD endpoint.

Zi-Han Lei, Hao Liang, Qin Cheng et al. · Pharmaceutics · 0 citations